Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has experienced a decline in its stock price by -0.97 compared to its previous closing price of 21.57. However, the company has seen a fall of -4.69% in its stock price over the last five trading days. businesswire.com reported 2025-06-25 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strateg.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a price-to-earnings ratio of 15.55x that is above its average ratio. Additionally, the 36-month beta value for ACAD is 0.64. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 6 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACAD is 166.02M and currently, short sellers hold a 9.30% ratio of that float. The average trading volume of ACAD on July 02, 2025 was 2.20M shares.
ACAD’s Market Performance
The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a -4.69% decrease in the past week, with a -0.97% drop in the past month, and a 28.60% gain in the past quarter. The volatility ratio for the week is 4.09%, and the volatility levels for the past 30 days are at 3.74% for ACAD. The simple moving average for the last 20 days is -3.47% for ACAD’s stock, with a simple moving average of 21.89% for the last 200 days.
Analysts’ Opinion of ACAD
Many brokerage firms have already submitted their reports for ACAD stocks, with Deutsche Bank repeating the rating for ACAD by listing it as a “Buy.” The predicted price for ACAD in the upcoming period, according to Deutsche Bank is $35 based on the research report published on May 21, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $22. The rating they have provided for ACAD stocks is “Hold” according to the report published on February 11th, 2025.
Guggenheim gave a rating of “Neutral” to ACAD, setting the target price at $20 in the report published on January 03rd of the current year.
ACAD Trading at 9.22% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.34% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Brege Laura, who sale 14,446 shares at the price of $21.78 back on Jun 04 ’25. After this action, Brege Laura now owns 15,095 shares of Acadia Pharmaceuticals Inc, valued at $314,634 using the latest closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.23. The total capital return value is set at 0.28. Equity return is now at value 37.24, with 23.03 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.66.
Currently, EBITDA for the company is 100.16 million with net debt to EBITDA at -1.68. When we switch over and look at the enterprise to sales, we see a ratio of 3.43. The receivables turnover for the company is 8.76for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In conclusion, Acadia Pharmaceuticals Inc (ACAD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
